Crossmark

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as first line chemotherapy for patients with unresectable advanced esophageal cancer in Japan

Crossref DOI link: https://doi.org/10.1007/s10388-025-01144-5

Published Online: 2025-07-12

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kakinuma, Hirohito

Takada, Daisuke

Itoshima, Hisashi

Kunisawa, Susumu

Moriwaki, Kensuke

Honda, Michitaka

Fushimi, Kiyohide

Imanaka, Yuichi https://orcid.org/0000-0003-4613-2159
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (JP23H00448)
License Information

Text and Data Mining valid from 2025-07-12

Version of Record valid from 2025-07-12
More Information

Article History

Received: 15 April 2025

Accepted: 30 June 2025

First Online: 12 July 2025

Declarations

:

: The authors declare no conflicts of interest in association with the present study.

: This investigation was conducted in accordance with the principles of the Declaration of Helsinki.

Document is current

Any future updates will be listed below